Before 2020, the importance of robust and resilient supply chains and how they can affect access to life-saving treatments probably wasn’t top of mind for many outside the biopharmaceutical industry. Then, in a sudden and very real way, the COVID-19 pandemic showed just how critical it is to have manufacturing facilities capable of scaling up quickly to meet an urgent public health demand. America’s biopharmaceutical companies rose to the challenge, researching and developing vaccines and therapeutics in record time, ramping up manufacturing to meet global demand and avoiding sustained supply chain disruptions.
